Population Pharmacokinetics of the Interleukin-23 Inhibitor Risankizumab in Subjects with Psoriasis and Crohn’s Disease: Analyses of Phase I and II Trials

• Published in: Clinical pharmacokinetics Vol. 58; no. 3; pp. 375 - 387
• Main Authors: Suleiman, Ahmed A., Khatri, Amit, Minocha, Mukul, Othman, Ahmed A.
• Format: Journal Article
• Language: English
• Published: Cham Springer International Publishing 01.03.2019; Springer Nature B.V
• Subjects: Administration, Intravenous; Adult; Aged; Antibodies, Monoclonal - administration & dosage; Antibodies, Monoclonal - pharmacokinetics; Antibodies, Monoclonal - therapeutic use; Antibodies, Monoclonal, Humanized - administration & dosage; Antibodies, Monoclonal, Humanized - pharmacokinetics; Antibodies, Monoclonal, Humanized - therapeutic use; Arthritis; Biological Availability; Biological Variation, Population - drug effects; Body Weight - drug effects; Clinical trials; Crohn Disease - blood; Crohn Disease - drug therapy; Crohn Disease - ethnology; Crohn's disease; Cytokines; Female; Humans; Immunoglobulins; Inflammatory bowel disease; Injections, Subcutaneous; Interleukin-23 - antagonists & inhibitors; Internal Medicine; Male; Medicine; Medicine & Public Health; Middle Aged; Models, Biological; Monoclonal antibodies; Original; Original Research Article; Patients; Pharmacokinetics; Pharmacology/Toxicology; Pharmacotherapy; Psoriasis; Psoriasis - blood; Psoriasis - drug therapy; Psoriasis - ethnology; Serum Albumin - drug effects; Studies
• ISSN: 0312-5963; 1179-1926; 1179-1926
• DOI: 10.1007/s40262-018-0704-z

Background and Objectives Risankizumab is a humanized anti-interleukin-23 monoclonal antibody in development for the treatment of several inflammatory diseases. This work characterized the pharmacokinetics of risankizumab and evaluated covariates that may affect its exposures using phase I and II trial data in subjects with psoriasis and Crohn’s disease. Methods Plasma concentration measurements from a phase I study and a phase II study in subjects with psoriasis ( n  = 157; single doses of 0.01–5 mg/kg intravenously, 0.25–1 mg/kg subcutaneously, and 18 mg subcutaneously, and multiple doses of 90 and 180 mg subcutaneously), and a phase II study in subjects with Crohn’s disease ( n  = 115; doses of 200 or 600 mg intravenously every 4 weeks followed by 180 mg subcutaneously every 8 weeks) were analyzed using non-linear mixed-effects modeling. The model was qualified using bootstrap and simulation-based diagnostics. Results A two-compartment model with first-order absorption and elimination described the pharmacokinetics of risankizumab. Considering the body weight and baseline albumin central tendency differences between disease populations, risankizumab clearance, steady-state volume of distribution, and terminal-phase elimination half-life were estimated to be approximately 0.35 L/day, 11.7 L, and 27 days, respectively, for a typical 90-kg subject with psoriasis with an albumin level of 42 g/L, and 0.31 L/day, 8.45 L, and 22 days, respectively, for a typical 65-kg subject with Crohn’s disease with an albumin level of 37 g/L. Risankizumab absolute subcutaneous bioavailability and absorption rate constant were 72% and 0.18 day −1 , respectively. Inter-individual variability for clearance was 37%. Conclusions Risankizumab displayed pharmacokinetic characteristics typical for an IgG1 monoclonal antibody with no apparent target-mediated disposition. Accounting for the effects of body weight and baseline albumin explained the small differences in the pharmacokinetics of risankizumab between psoriasis and Crohn’s disease, with no further differences between the patient populations.